Search

Your search keyword '"Iñarrairaegui, Mercedes"' showing total 320 results

Search Constraints

Start Over You searched for: Author "Iñarrairaegui, Mercedes" Remove constraint Author: "Iñarrairaegui, Mercedes"
320 results on '"Iñarrairaegui, Mercedes"'

Search Results

1. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

4. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

10. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

14. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

15. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules

18. Deep learning predicts sensitivity to atezolizumab-bevacizumab from digital slides of hepatocellular carcinoma

19. Quality of life in patients with unresectable hepatocellular carcinoma treated with selective internal radiation therapy (SIRT) and Nivolumab: a sub-analysis of the NASIR-HCC trial

22. Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies

24. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.

25. Results in Hepatocellular Carcinoma

26. Radioembolization-Induced Liver Disease

27. Radioembolization: Concepts and Procedures

28. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

29. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

33. Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma

35. Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under 1st line therapy (GOING trial). Interim analysis and safety profile

36. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

38. A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits

40. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

42. Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.

43. Neoantigens as potential vaccines in hepatocellular carcinoma

44. Decreased Long‐Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

48. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

Catalog

Books, media, physical & digital resources